{"name": "Theratechnologies",
 "permalink": "theratechnologies",
 "crunchbase_url": "http://www.crunchbase.com/company/theratechnologies",
 "homepage_url": "http://www.theratech.com",
 "blog_url": "",
 "blog_feed_url": "",
 "twitter_username": "",
 "category_code": "biotech",
 "number_of_employees": null,
 "founded_year": null,
 "founded_month": null,
 "founded_day": null,
 "deadpooled_year": null,
 "deadpooled_month": null,
 "deadpooled_day": null,
 "deadpooled_url": null,
 "tag_list": "",
 "alias_list": "",
 "email_address": "communications@theratech.com",
 "phone_number": "514 336-7800",
 "description": "",
 "created_at": "Tue Sep 07 01:45:02 UTC 2010",
 "updated_at": "Tue Sep 07 01:49:31 UTC 2010",
 "overview": "\u003Cp\u003ETheratechnologies Inc., a biopharmaceutical company, engages in the discovery of therapeutic products for commercialization. The company\u00e2\u20ac\u2122s proprietary technologies include Long Acting Peptides, a peptide stabilization technology that increases the target protein\u00e2\u20ac\u2122s resistance to enzymatic degradation. Its lead product is tesamorelin, which completed its phase III clinical trial for the treatment of HIV-associated lipodystrophy and is in phase II clinical trials for the treatment of mild cognitive impairment and growth hormone deficient abdominal obesity. The company also develops Acute kidney injury, a preclinical stage product. It has a license agreement with PDC Biotech GmbH to use the antagonists of the prostaglandin F2a receptor in pre-term labor and primary dysmenorrheal; and OctoPlus N.V. to develop and commercialize GLP-1 portfolio of analogues. The company also has a collaboration and licensing agreement with EMD Serono, Inc. for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy. The company was founded in 1993 and is headquartered in Montreal, Canada.\u003C/p\u003E",
 "image":
  {"available_sizes":
    [[[150,
       62],
      "assets/images/resized/0010/0792/100792v1-max-150x150.png"],
     [[151,
       63],
      "assets/images/resized/0010/0792/100792v1-max-250x250.png"],
     [[151,
       63],
      "assets/images/resized/0010/0792/100792v1-max-450x450.png"]],
   "attribution": null},
 "products":
  [],
 "relationships":
  [{"is_past": false,
    "title": "President \u0026 CEO",
    "person":
     {"first_name": "John-Michel",
      "last_name": "T. Huss",
      "permalink": "john-michel-t-huss",
      "image": null}},
   {"is_past": false,
    "title": "Senior Executive Vice President and CFO",
    "person":
     {"first_name": "Luc",
      "last_name": "Tanguay",
      "permalink": "luc-tanguay",
      "image": null}}],
 "competitions":
  [],
 "providerships":
  [],
 "total_money_raised": "$0",
 "funding_rounds":
  [],
 "investments":
  [],
 "acquisition": null,
 "acquisitions":
  [],
 "offices":
  [{"description": "",
    "address1": "2310 Alfred-Nobel Blvd.",
    "address2": "",
    "zip_code": "H4S 2B4",
    "city": "Montr\u00c3\u00a9al, Qu\u00c3\u00a9bec",
    "state_code": null,
    "country_code": "CAN",
    "latitude": null,
    "longitude": null}],
 "milestones":
  [],
 "ipo": null,
 "video_embeds":
  [],
 "screenshots":
  [],
 "external_links":
  []}